SCHEMBL434802

SCHEMBL434802

CC(=O)N(C)C1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.50
FAAH O00519 1/20 0.50
PHGDH O43175 1/20 0.50
MGLL Q99685 1/20 0.50
ALDH1A1 P00352 1/20 0.48
RAB9A P51151 3/20 0.45
ADH1C P00326 2/20 0.44
ADH1A P07327 2/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 2/20 0.42
POLB P06746 3/20 0.40
NPC1 O15118 2/20 0.40
ABCC1 P33527 1/20 0.40
KCNH2 Q12809 1/20 0.39
LIPE Q05469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9462674 1.00 ATM (0.50) ATMFAAHPHGDHMGLLALDH1A1
SCHEMBL19569734 1.00 ATM (0.50) ATMFAAHPHGDHMGLLALDH1A1
SCHEMBL2223070 0.97 ATM (0.47) ATMFAAHPHGDHMGLLALDH1A1
SCHEMBL14589116 0.95
SCHEMBL22622819 0.89 ATM (0.44) ATMFAAHPHGDHMGLLALDH1A1
SCHEMBL24942186 0.88 ATM (0.42) ATMFAAHPHGDHMGLLALDH1A1
SCHEMBL5506106 0.87
Formamide SCHEMBL28307664 0.87 ADH1A (0.43) ATMFAAHPHGDHMGLLALDH1A1
Formic Acid SCHEMBL27753182 0.86 ALDH1A1 (0.42) ATMFAAHPHGDHMGLLALDH1A1
SCHEMBL17704770 0.82 FAAH (0.52) ATMFAAHPHGDHMGLLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US claimed
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2014-04-10 US claimed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US claimed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US claimed
CN-101945858-A As the pyrazinones derivative of insulin secretion stimulant, the method that obtains them and the purposes in the treatment diabetes thereof MERCK PATENT GMBH 2011-01-12 CN claimed
EP-2250156-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2010-11-17 EP claimed
CN-101611005-A Be used as the acetophenones of the replacement of PDE4 inhibitor LEO PHARMA AS (DK) 2009-12-23 CN claimed
EP-2125736-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS Leo Pharma A/S (DK) 2009-12-02 EP claimed
WO-2009109259-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-11 WO claimed
WO-2008077404-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA A/S (DK) 2008-07-03 WO claimed
EP-1187613-B9 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2006-10-25 EP claimed
EP-1187613-B1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2006-08-09 EP claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
CN-118851932-A Method for preparing alpha-amino acid derivative 中国科学院大连化学物理研究所 2024-10-29 CN disclosed
US-20230387464-A1 Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery MU IONIC SOLUTIONS CORPORATION (JP) 2023-11-30 US disclosed
WO-2023227703-A1 SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS ASTRAZENECA AB (SE) 2023-11-30 WO disclosed
EP-0167168-A2 Silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 1986-01-08 EP disclosed
US-4329347-A Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril BOEHRINGER INGELHEIM GMBH (DE) 1982-05-11 US disclosed
US-4153794-A ANTIHISTAMINES, ANTICONVULSANTS, EXPECTORANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1979-05-08 US disclosed
US-4091220-A RESPIRATORY TRACK FLUID SECRETION STIMULATORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1978-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES GLP1R, GPR119, IAPP ATM 1694/4885FAAH 4269/4885PHGDH 2811/4885
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes GLP1R, IAPP, INSR ATM 2210/4885FAAH 4182/4885PHGDH 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.